Product Center
Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-30
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification!
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-30 11:32
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
Specialized, Refined, Unique, and Innovative Small and Medium-Sized Enterprises refer to those that focus on segmented markets, have outstanding innovation capabilities, a high market share, and strong development potential. The acquisition of this title represents authoritative recognition of the enterprise's specialization, refinement, uniqueness, and innovation. Ab&B Bio will also adhere to an innovation-driven approach, making products more specialized, quality more refined, and its brand stronger, so that China can use global innovative vaccines and the world can use high-quality Chinese vaccines.
The recognition of a National High-Tech Enterprise is one of the most authoritative evaluations of a company's comprehensive strength in the field of scientific and technological innovation. This recognition is a comprehensive assessment by authoritative national departments of the research and development management level, the quantity and quality of independent intellectual property rights, the ability to transform scientific and technological achievements, growth potential, and talent structure of the enterprise, reflecting high recognition of its innovation capability and development potential. Yither Bio will continue to enhance its research and development capabilities, accelerate the transformation of scientific and technological achievements, and provide a source of vitality for the company's innovative vaccine development.
Relevant information
-
The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. - Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
